NCT05970809 (CS-SAGA-001) is a NA clinical trial of SAGA-001 (A) in Male Pattern Baldness, sponsored by StimuSIL.

Who is sponsoring NCT05970809?

NCT05970809 is sponsored by StimuSIL.

What drugs are being tested in NCT05970809?

Interventions in NCT05970809: SAGA-001 (A), SAGA-001 (B).

What condition does NCT05970809 study?

NCT05970809 studies Male Pattern Baldness, Androgenetic Alopecia, Hair Loss/Baldness, Hair Loss, Pattern Baldness.

Is NCT05970809 still recruiting?

NCT05970809 is currently completed. Last updated 30 May 2025.

Last reviewed 2025-05-30 · How we verify

NCT05970809: CS-SAGA-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss

Completed NA Last updated 30 May 2025

What this trial tests

NA trial testing SAGA-001 (A) in Male Pattern Baldness in 82 participants. Completed in 24 October 2024.

Timeline

1 June 2023

Primary endpoint
30 August 2024

24 October 2024

Quick facts

Lead sponsor	StimuSIL
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	82
Start date	1 June 2023
Primary completion	30 August 2024
Estimated completion	24 October 2024
Sites	2 locations across Turkey (Türkiye)

Drugs / interventions tested

SAGA-001 (A)
SAGA-001 (B)

Conditions studied

Male Pattern Baldness — all drugs for Male Pattern Baldness →
Androgenetic Alopecia — all drugs for Androgenetic Alopecia →
Hair Loss/Baldness — all drugs for Hair Loss/Baldness →
Hair Loss — all drugs for Hair Loss →

Sponsor

StimuSIL

Who can join

Adults 22 to 55, male only, with Male Pattern Baldness or Androgenetic Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study. Device A has novel microneedles, lasers, and additional metal microneedles, while Device B only has novel microneedles and lasers. Participants will receive 12 treatments with either Device A or Device B over the course of 24 weeks. Treatments will be performed on-site every two weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

From mechanism to applications: Advanced microneedles for clinical medicine.
Yang Y, Sun H, Sun X, Wang Y, et al · · 2025 · cited 9× · PMID 40463395 · DOI 10.1016/j.bioactmat.2025.04.025

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05970809 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by StimuSIL
Last refreshed: 30 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05970809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing